电邮这篇文章 The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council
- 作者: Andrianova VS1, Beliaeva AV2, Bolotina LV3, Vazhenina AA4, Varlamova SE5, Vladimirov VI6, Vladimirova LY.7, Voznyi EK8, Demidov SM9, Zhukov NV10, Zhukova LG11, Imianitov EN12, Kovalenko EI11, Kogoniia LM13, Konstantinova MM14, Lan SA9, Lichinitser MR11, Manziuk LV11, Manikhas AG15, Mukhametshina GZ16, Semiglazov VF12, Semiglazova TI.12, Seregina GV1, Stroiakovskii DL17, Ter-Ovanesov MD1, Chichkanova AS18
-
隶属关系:
- City Clinical Hospital №40 of Moscow Department of Health
- OOO «Eisai»
- P.A.Herzen Moscow Cancer Research Institute of the Ministry of Health of the Russian Federation
- District Clinical Hospital
- A.I.Burnazyan Federal Medical and Biophysical Center of FMBA of Russia
- Pyatigorsk Oncology Dispensary. Russian Federation
- Rostov Scientific Research Institute of Oncology of the Ministry of Health of the Russian Federation
- City Clinical Hospital №57 of Moscow Department of Health
- City Clinical Hospital №40
- D.Rogachev FSBI FSCC PHOI of the Ministry of Health of the Russian Federation
- N.N.Blokhin Russian Cancer Research Center
- N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation
- M.F.Vladimirsky Moscow Regional Research Clinical Institute
- A.V.Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation
- City Clinical Oncology Dispensary
- Republic Clinical Oncology Dispensary of the Ministry of Health of the Russian Federation
- Moscow City Oncology Hospital №62 of Moscow Department of Health
- Nizhny Novgorod Regional Oncology Dispensary
- 期: 卷 17, 编号 1 (2015)
- 页面: 5-8
- 栏目: Articles
- URL: https://bakhtiniada.ru/1815-1434/article/view/26974
- ID: 26974
如何引用文章
全文:
详细
作者简介
V Andrianova
City Clinical Hospital №40 of Moscow Department of Health129301, Russian Federation, Moscow, ul. Kasatkina, d. 7
A Beliaeva
OOO «Eisai»121099, Russian Federation, Moscow, Novinskii bul'var, d. 8
L Bolotina
P.A.Herzen Moscow Cancer Research Institute of the Ministry of Health of the Russian Federation125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3
A Vazhenina
District Clinical Hospital629001, Russian Federation, Salekhard, ul. Mira, d. 39
S Varlamova
A.I.Burnazyan Federal Medical and Biophysical Center of FMBA of Russia123098, Russian Federation, Moscow, ul. Marshala Novikova, d. 23
V Vladimirov
Pyatigorsk Oncology Dispensary. Russian FederationPiatigorsk, pr. Kalinina, d. 31
L Vladimirova
Rostov Scientific Research Institute of Oncology of the Ministry of Health of the Russian Federation344037, Russian Federation, Rostov-na-Donu, 14-ia liniia, d. 63
E Voznyi
City Clinical Hospital №57 of Moscow Department of Health105077, Russian Federation, Moscow, ul. 11-ia Parkovaia, d. 32
S Demidov
City Clinical Hospital №40620102, Russian Federation, Ekaterinburg, ul. Volgogradskaia, d. 189
N Zhukov
D.Rogachev FSBI FSCC PHOI of the Ministry of Health of the Russian Federation117198, Russian Federation, Moscow, ul. Samory Mashela, d. 1
L Zhukova
N.N.Blokhin Russian Cancer Research Center115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E Imianitov
N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68
E Kovalenko
N.N.Blokhin Russian Cancer Research Center115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
L Kogoniia
M.F.Vladimirsky Moscow Regional Research Clinical Institute129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
M Konstantinova
A.V.Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation117997, Russian Federation, Moscow, ul. Bol'shaia Serpukhovskaia, d. 27
S Lan
City Clinical Hospital №40620102, Russian Federation, Ekaterinburg, ul. Volgogradskaia, d. 189
M Lichinitser
N.N.Blokhin Russian Cancer Research Center115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
L Manziuk
N.N.Blokhin Russian Cancer Research Center115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A Manikhas
City Clinical Oncology Dispensary197022, Russian Federation, Saint Petersburg, 2-ia Berezovaia alleia, d. 3/5, pr-t Veteranov, d. 56
G Mukhametshina
Republic Clinical Oncology Dispensary of the Ministry of Health of the Russian Federation420029, Russian Federation, Kazan', Sibirskii trakt, d. 29
V Semiglazov
N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68
T Semiglazova
N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation197758, Russian Federation, Saint Petersburg, p. Pesochnyi, ul. Leningradskaia, d. 68
G Seregina
City Clinical Hospital №40 of Moscow Department of Health129301, Russian Federation, Moscow, ul. Kasatkina, d. 7
D Stroiakovskii
Moscow City Oncology Hospital №62 of Moscow Department of Health143423, Russian Federation, Moskovskaia oblast', p. Istra, d. 27
M Ter-Ovanesov
City Clinical Hospital №40 of Moscow Department of Health129301, Russian Federation, Moscow, ul. Kasatkina, d. 7
A Chichkanova
Nizhny Novgorod Regional Oncology Dispensary603126, Russian Federation, Nizhnii Novgorod, ul. Rodionova, d. 190
参考
- Yoshida T, Ozawa Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial - mesenchymal transition (EMT) to mesenchymal - epithelial transition (MET) states. Br J Cancer 2014; 110 (6): 1497-505.
- Nabholtz J.M, Thuerlimann B, Beswoda W.R et al. TaxotereR (T) improves survival over mitomycin C vinblastine (MV) in patients (PTS) with metastatic breast cancer (MBC) who have failed an anthracycline (ANT) containing regimen: final results of a phase III randomized trial. Proc Am Soc Clin Oncol 1998; 17: 101a.
- Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy vs. treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open - label randomised study. Lancet 2011; 377: 914-23.
- Kaufman P.A, Cortes J, Awada A et al. A phase III, open - label, randomized study of eribulin mesylate vs. capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthra - cyclines and taxanes: subgroup analyses. J Clin Oncol 2013; 31 (suppl.; abstr. 1049).
- Инструкция по медицинскому применению препарата Халавен [РУ ЛП-001782 от 24.07.2012 (с изменениями от 25.11.14 г.)].
- Twelves C, Cortes J, Vandat L et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat (2014) 148: 553-61.
补充文件
